A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer

Trial Profile

A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors OncoGenex Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2014 Pharmacokinetic results presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 17 Nov 2008 Actual patient number identified as 821 from ClinicalTrials.gov.
    • 17 Nov 2008 Actual trial completion date identified as September 2007 from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top